Program
adebrelimab
Also written as “SHR-1316”, “Adebrelimab” and “Adebrelimab Injection”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Pancreatic Neoplasms · Neoplasms · Breast Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 4938 open or running | phase 3since Oct 16, 2018 | Apr 8, 2017 | Dec 2026phase 2 · NCT05482568 |
| Hansoh Pharmaceutical Group | 22 open or running | phase 2since Aug 13, 2026 | Jul 3, 2025 | Mar 30, 2028phase 2 · NCT07824882 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 36 studies since Apr 8, 2017.
- Nov 13, 2025Phase 3 study in Advanced Biliary Tract CancerJiangsu HengRui Medicine · NCT07229625 · 604 planned · China
- Nov 14, 2025Phase 2 study in Lung NeoplasmsJiangsu HengRui Medicine · NCT07241767 · 200 planned · China
- Dec 9, 2025Phase 2 study in Locally Advanced or Metastatic Pancreatic Cancer WithJiangsu HengRui Medicine · NCT07296341 · 60 planned · China
- Jan 30, 2026Phase 3 study in Carcinoma, Transitional CellJiangsu HengRui Medicine · NCT07393542 · 453 planned · China
- Feb 25, 2026Phase 3 study in Locally Advanced Resectable Rectal CancerJiangsu HengRui Medicine · NCT07454720 · 165 planned · China
- Apr 3, 2026Phase 3 study in Locally Advanced Gastric or Gastroesophageal Junction CancerJiangsu HengRui Medicine · NCT07522151 · 874 planned · China
- Jun 25, 2026Phase 3 study in Triple Negative Breast NeoplasmsJiangsu HengRui Medicine · NCT07679360 · 1,000 planned · China
- Jul 2, 2026Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT07691762 · 690 planned · China
- Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerJiangsu HengRui Medicine · NCT07704645 · 180 planned · China
- Aug 13, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedHansoh Pharmaceutical Group · NCT07824882 · 76 planned · China
- Aug 28, 2026Phase 2 study in Small Cell Lung CarcinomaJiangsu HengRui Medicine · NCT07798947 · 120 planned · China
- Sep 2, 20262 phase 2 studiesJiangsu HengRui Medicine · NCT07806058, NCT07863167
- Oct 19, 20262 phase 3 studiesJiangsu HengRui Medicine · NCT07896005, NCT07900789
- Oct 29, 2026Primary completion moved from 2031-04 to 2031-09Date moved laterphase 3 · +5 months · NCT07691762
Ahead
- Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourJiangsu HengRui Medicine · NCT06915142
- Dec 2026Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerJiangsu HengRui Medicine · NCT05482568
- Dec 30, 2026Primary completion: phase 2 study in Biliary Tract NeoplasmsJiangsu HengRui Medicine · NCT06465563
- Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckJiangsu HengRui Medicine · NCT07059221
TargetBeta
“An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| durvalumabrule | AstraZeneca | phase 4 | 102 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 51 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07900789Systemic Treatment-naïve Pancreatic Cancer · China | 3 | Not yet recruiting | Jiangsu HengRui Medicine | Nov 30, 2030 | 825 |
| NCT07896005Carcinoma, Non-Small-Cell Lung · China | 3 | Not yet recruiting | Jiangsu HengRui Medicine | Feb 2031 | 436 |
| NCT07863167Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Dec 30, 2028 | 660 |
| NCT07806058Pancreatic Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2028 | 140 |
| NCT07798947Small Cell Lung Carcinoma · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2028 | 120 |
| NCT07824882Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Hansoh Pharmaceutical Group | Mar 30, 2028 | 76 |
| NCT07704645Resectable Non-small Cell Lung Cancer · China | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Jun 2028 | 180 |
| NCT07691762Carcinoma, Hepatocellular · China | 3 | Not yet recruiting | Jiangsu HengRui Medicine | Sep 2031 | 690 |
| NCT07679360Triple Negative Breast Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2030 | 1,000 |
| NCT07522151Locally Advanced Gastric or Gastroesophageal Junction Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2029 | 874 |
| NCT07454720Locally Advanced Resectable Rectal Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Nov 2032 | 165 |
| NCT07393542Carcinoma, Transitional Cell · China | 3 | Recruiting | Jiangsu HengRui Medicine | Jan 31, 2028 | 453 |
| NCT07296341Locally Advanced or Metastatic Pancreatic Cancer With · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 2027 | 60 |
| NCT07241767Lung Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Nov 2027 | 200 |
| NCT07229625Advanced Biliary Tract Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2029 | 604 |
| NCT07168200Advanced Cervical Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Apr 2028 | 720 |
| NCT07118527Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Jiangsu HengRui Medicine | Oct 2030 | 600 |
| NCT07111832Triple Negative Breast Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Mar 2028 | 400 |
| NCT07073534Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2027 | 203 |
| NCT07063407Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Apr 30, 2026 | 50 |
| NCT07059221Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Jiangsu HengRui Medicine | Mar 2027 | 210 |
| NCT07009457Widespread Small Cell Lung Cancer · China | 1 | Active, not recruiting | Jiangsu HengRui Medicine | Sep 2027 | 24 |
| NCT06915142Advanced Malignant Tumour · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 300 |
| NCT06879145Muscular Invasive Bladder Cancer (MIBC) · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 2031 | 740 |
| NCT06592625Untreated Early-stage or Locally Advanced Breast Cancer · China | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Feb 28, 2026 | 60 |
| NCT06465563Biliary Tract Neoplasms · China | 2 | Active, not recruiting | Jiangsu HengRui Medicine | Dec 30, 2026 | 93 |
| NCT06474468Esophageal Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 2026 | 148 |
| NCT06417554Advanced Solid Tumors · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 31, 2031 | 80 |
| NCT06350006CLDN18.2-positive Advanced Solid Tumor · China | 1 | Recruiting | Jiangsu HengRui Medicine | Dec 30, 2027 | 924 |
| NCT06335355Non-squamous Non-small Cell Lung Cancer · China | 3 | Not yet recruiting | Jiangsu HengRui Medicine | Oct 2028 | 401 |
| NCT06247956Esophageal Squamous Cell Carcinoma · China | 2 | Active, not recruiting | Jiangsu HengRui Medicine | Dec 30, 2025 | 153 |
| NCT06237257Locally Advanced Cervical Cancer · China | 2 | Active, not recruiting | Jiangsu HengRui Medicine | Dec 2024 | 56 |
| NCT06222879Breast Neoplasms · China | 2 | Recruiting | Jiangsu HengRui Medicine | Oct 31, 2026 | 350 |
| NCT06092268Advanced Solid Tumors | 2 | Not yet recruiting | Jiangsu HengRui Medicine | Dec 2025 | 270 |
| NCT05794477Advanced Solid Tumor · China | 2 | Completed | Jiangsu HengRui Medicine | Aug 20, 2024 | 16 |
| NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2027 | 258 |
| NCT05482568Advanced Non-small Cell Lung Cancer · China | 2 | Recruiting | Jiangsu HengRui Medicine | Dec 2026 | 324 |
| NCT05444088Advanced Hepatocellular Carcinoma · China | 2 | Recruiting | Jiangsu HengRui Medicine | Jun 30, 2026 | 129 |
| NCT05416775Advanced Non-small Cell Lung Cancer · China | 2 | Recruiting | Jiangsu HengRui Medicine | Jun 30, 2026 | 168 |
| NCT05353361Breast Neoplasms · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Dec 31, 2025 | 402 |
| NCT05198817Advanced Malignant Tumors · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jan 31, 2023 | 240 |
| NCT05082545Advanced Malignant Tumors · Australia | 1 | Completed | Jiangsu HengRui Medicine | Jul 17, 2023 | 19 |
| NCT04979390Neoplasms | 1 | UNKNOWN | Jiangsu HengRui Medicine | Feb 10, 2022 | 15 |
| NCT04691063Small Cell Lung Carcinoma · China | 3 | By invitation | Jiangsu HengRui Medicine | May 15, 2025 | 486 |
| NCT04316364Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Jiangsu HengRui Medicine | Apr 15, 2023 | 537 |
| NCT04041011Small Cell Lung Carcinoma · China | 1 | Completed | Jiangsu HengRui Medicine | Apr 23, 2021 | 23 |
| NCT03995472Advanced Malignancies · Australia, China | 1 | Completed | Jiangsu HengRui Medicine | Jan 12, 2023 | 14 |
| NCT03732508Advanced Esophageal Squamous Cell Cancer · China | 2 | UNKNOWN | Jiangsu HengRui Medicine | Nov 2019 | 30 |
| NCT03711305Small Cell Lung Carcinoma · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Oct 2022 | 462 |
| NCT03474289Neoplasms · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jan 30, 2019 | 134 |
| NCT03133247Advanced Solid Tumors · Australia | 1 | Completed | Jiangsu HengRui Medicine | Apr 9, 2019 | 37 |
How it is read
Names in the registry
- “SHR-1316”, 8 entries
- “Adebrelimab”, 6 entries
- “Adebrelimab Injection”, 4 entries
- “adebrelimab + SHR-A2009”, 3 entries
- “HRS-717 + HRS-4642+SHR-1316;”, 3 entries
Codes read as this program: SHR1316.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 8 studies
- Small Cell Lung Carcinoma, 6 studies
- Pancreatic Neoplasms, 3 studies
- Neoplasms, 3 studies
- Breast Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.